Clinical trials: Leucovorin
Metastatic Colorectal Cancer
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
The purpose of this study is to investigate the influence of dose selection of CPT-11 on toxicity, response and pharmacokinetics according to UGT1A1 genotype in colorectal cancer patients.
- Trial name
- NCT01523431
- Testing
- Irinotecan Injection [Camptosar], 5-fluorouracil, Leucovorin
- Where
- China
- Volunteers
- 583 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Advanced Solid Tumors, Metastatic Colorectal Cancer
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and 5-fluorouracil in patients with advanced solid tumors.
- Trial name
- NCT01238939
- Testing
- NK012 and 5-FU
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Rectal Cancer
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
Multimodality treatment that comprises preoperative fluoropyrimidine with concurrent radiotherapy followed by total mesorectal excision (TME) surgery and adjuvant fluoropyrimidine-based chemotherapy is recommended as a standard…
- Trial name
- FOBEAR (NCT04215731)
- Testing
- Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Restaging, Concomitant Chemoradiotherapy
- Where
- China
- Volunteers
- 582 people
- Sponsor
- Yanhong Deng
Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b
Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b
Gastric and gastro-oesophageal junction (GEJ) adenocarcinomas rank as the fifth leading cause of cancer globally. The standard treatment for resectable non-metastatic cT2-T4NX gastric or GEJ adenocarcinoma is perioperative FLOT…
- Trial name
- BEMAFLOT (NCT06967987)
- Testing
- Bemarituzumab + Flot regimen
- Where
- 12 sites in France
- Sponsor
- Institut Cancerologie de l'Ouest
Pancreatic Cancer
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
LDE225 is a new medicine that blocks the Hedgehog (Hh) pathway. The Hh pathway is a cascade of molecular events that control cell growth and have been linked with the development of many human cancers, including pancreatic…
- Trial name
- NCT01485744
- Testing
- LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Colorectal Neoplasms
ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
To determine efficacy in the delivery of chronomodulated chemotherapy.
- Trial name
- NCT00385021
- Testing
- 5-Fluorouracil, leucovorin, oxaliplatin, avastin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Southwestern Regional Medical Center
Colorectal Cancer Stage IV
Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin
The purpose of this work is to verify prospectively what the rate of response after triple chemotherapy with mFOLFIRINOX in patients in IV stage of Colorectal Cancer who have already failed after at least two lines of dual…
- Trial name
- Re-Play (NCT05354817)
- Testing
- mFOLFIRINOX
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Colorectal Cancer
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as…
- Trial name
- NCT06547385
- Testing
- ONO-4578, ONO-4538, Capecitabine
- Where
- 9 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Pancreatic Cancer
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
In this study, Adebrelimab combined with NALIRIFOX conversion therapy was performed in subjects with locally advanced pancreatic cancer to evaluate the efficacy and safety of conversion therapy with immunotherapy combined with…
- Trial name
- NCT06475326
- Testing
- Adebrelimab, Oxaliplatin 100 MG, Irinotecan liposome
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Fudan University
Leukemia, Lymphoma
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as trimetrexate glucuronate and leucovorin, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Lymphoma, Sarcoma
- Trial name
- NCT00002738
- Testing
- leucovorin calcium, trimetrexate glucuronate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Neoplasms, Neoplasm Metastasis
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.
- Trial name
- AFFIRM (NCT00851084)
- Testing
- aflibercept, oxaliplatin, 5-FU
- Where
- 37 sites in Australia, Germany and 5 more
- Volunteers
- 268 people
- Sponsor
- Sanofi
Adenocarcinoma of the Lower Rectum
Non-Operative Management and Early Response Assessment in Rectal Cancer
The investigators' data from a phase I study of short course radiation therapy followed by chemotherapy showed 74% complete clinical response (cCR).
- Trial name
- NOM-ERA (NCT03904043)
- Testing
- Radiation therapy, FOLFOX regimen, CAPOX regimen
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Washington University School of Medicine
Hepatocellular Carcinoma
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
This study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with…
- Trial name
- NCT07522411
- Testing
- FOLFOX regimen, Immunotherapy, targeted therapy
- Volunteers
- 100 people
- Sponsor
- BinYong Liang
Metastatic Colorectal Cancer (CRC)
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the…
- Trial name
- HARMONi-GI3 (NCT07228832)
- Testing
- Drug: Ivonescimab Injection, Drug: Bevacizumab Injection
- Where
- 236 sites in United States, Belgium and 13 more
- Volunteers
- 600 people
- Sponsor
- Summit Therapeutics
Colorectal Cancer, Liver Metastases
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis of RAS wildtype.
- Trial name
- NCT03493048
- Testing
- Irinotecan, Cetuximab, 5-fluorouracil
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
This is a randomized, double-blinded, controlled, phase II study. The purpose is to evaluate efficacy and safety of the combination therapy of HAIC (Hepatic arterial infusion chemotherapy) with HLX10 (PD-1 antibody) and HLX04…
- Trial name
- NCT04947826
- Testing
- HAIC (Hepatic arterial infusion chemotherapy), HLX10 (PD-1 antibody), HLX04 (VEGF antibody)
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Colon Cancer Stage II, Colon Cancer Stage III
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
BACKGROUND: In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become a standard treatment.
- Trial name
- NCT05194878
- Testing
- neoadjuvant chemotherapyI, Colectomy, adjuvant chemotherapy
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Sun Yat-sen University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
This is an open-label, single-arm, single-center Phase Ib/II study to exploratorily evaluate the tolerability, safety, and efficacy of regorafenib and nivolumab plus chemotherapy in patients with unresectable advanced/recurrent…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT05394740
- Testing
- Regorafenib, Nivolumab, CapeOX
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- National Cancer Center Hospital East
Acute Lymphoblastic Leukemia
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
The purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute lymphoblastic leukemia (ALL) in infants.
- Trial name
- NCT02553460
- Testing
- ITMHA, Dexamethasone, Mitoxantrone
- Where
- 15 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- St. Jude Children's Research Hospital
Stomach Neoplasms
Oxaliplatin in Gastric Cancer
To determine the objective response to oxaliplatin/5FU/leucovorin combination chemotherapy in patients with advanced unresectable or metastatic gastric cancer.
- Trial name
- NCT00263354
- Testing
- Oxaliplatin
- Volunteers
- 20 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.